Over the past 50 years Memorial Sloan Kettering has made many important contributions to urologic oncology. Listed below are some of the most significant and enduring scientific contributions from urologists, medical oncologists, radiation therapists, pathologists, and other physicians and scientists at MSKCC. Many of the published papers that documented these contributions were co-authored by fellows and residents.
Bladder Cancer
| Year | Contributions in Treatment and Research |
|---|---|
| 1943-1949 | Techniques of Radical Cystectomy and Pelvic Lymphadenectomy |
| 1952 | Dr. Myron Melamed Describes Carcinoma-In-Situ of the Urothelium |
| 1956 | Technique of Urethrectomy |
| 1959 | Preoperative Irradiation and Radical Cystectomy |
| 1973 | Technique of In-Continuity Urethrectomy during Radical Cystectomy |
| 1974 | Outpatient Cystoscopy and Fulguration of Recurrent Superficial Papillary Bladder Tumors |
| 1975 | Identification and Characterization of Tumor-Associated Antigens |
| 1979 | Diagnostic Value of Urinary Cytology and Flow Cytometry |
| 1979-1984 | Intravesical Bacillus Calmette-Guerin (BCG) for Superficial Bladder Tumors and Randomized Trials of BCG, used for FDA Approval |
| 1981 | Ureteroscopic Destruction of Upper Tract Tumors |
| 1983 | Neoadjuvant M-VAC Chemotherapy and Radical Cystectomy |
| 1983-1992 | M-VAC Chemotherapy Cures Transitional Cell Carcinoma |
| 1983-1995 | Bladder-Sparing Strategies for Invasive Bladder Cancer |
| 1989 | Prognostic Significance of Lewis Blood Group Antigen |
| 1989-1999 |
G-CSF Effective with M-VAC Chemotherapy |
| 1992-1999 | Molecular Analysis (Rb, p53, mdm22, p16, p21, INK4A) |
| 1995-1999 | ITP Chemotherapy Improves Survival. and Post-Chemotherapy Surgery Found Beneficial |
| 1997 | New Staging for Bladder Cancer (Generated by Memorial Sloan Kettering’s Department of Urology and Pathology) Adopted by AJCC/UICC |
| 2003-2005 | Defined Survival Benefit Related to the Quality of the Pelvic Lymph Node Dissection in Patients Undergoing Radical Cystectomy Defined Refractory Carcinoma-In-Situ |
Prostate Cancer
| Contributions in Treatment and Research | |
|---|---|
| 1950-1960 | Ablative Surgery Adrenalectomy Exenteration for Locoregional Cancers |
| 1970 | Whitmore Staging System (AJCC) Technique of Retropubic I125 Implantation Natural History Defined |
| 1974 | Flutamide Polyamine |
| 1993 | Cloning of PSMA Gene Prostate-Specific Monoclonal Antibodies Neoadjuvant Hormonal Therapy and Radical Prostatectomy Three-Dimensional Conformal Radiation Therapy with Intensity Modulation |
| 1995 | Flutamide Withdrawal Syndrome |
| 1999 | Prognostic Nomograms Nerve Grafts with Radical Prostatectomy Quality of Life, Utility Assessment |
| 2004-2006 | Surgeon as an Independent Predictor of Outcomes |
Testis Cancer
| Contributions in Treatment and Research | |
|---|---|
| 1960 | Technique of Retroperitoneal Lymph Node Dissection |
| 1972-7980 | Cisplatin-Based Combination Chemotherapy VAB-I through VAB-VI Protocols Hydration for High-Dose Cisplatin Chemotherapy Salvage Surgery Post-Chemotherapy Adjuvant Chemotherapy |
| 1979 | Surveillance for Stage I Nonseminomatous Germ Cell Testis Tumors |
| 1983 | Risk-Adjusted Treatment Strategies Salvage Chemotherapies |
| 1988 | Marker Gene I(12)p |
| 1997 | Staging System Incorporating Tumor Markers Defined Mechanism of TP53 Mutations and Resistance |
Renal Cancer
| Contributions in Treatment and Research | |
|---|---|
| 1949 | Technique of Radical Nephrectomy |
| 1975 | Tumor Vaccine Developed Monoclonal Antibodies |
| 1979 | Partial Nephrectomy in Patients with Normal Contralateral Kidney |
| 1997 | Histologic and Molecular Genetic Classification |
| 1998 | Randomized Trials of Cis-Retinoic Acid ± Interferon |
| 1997-2000 | Prognostic Factors and Nomogram |
| 2006 | Partial Nephrectomy Prevents Chronic Kidney Disease |
Penile And Urethral Cancer
| Contributions in Treatment and Research | |
|---|---|
| 1956 | Technique of Radical Groin Dissection |
| 1983 | Extended Radical Excision (Pubectomy, Emasculation) |